Ticker: CHRS

Coherus Oncology, Inc. (NASDAQ: CHRS) has reported its financial results for the second quarter of 2025. The company continues to navigate the aftermath of significant strategic changes following the divestiture of its UDENYCA biosimilar business. Financial Performance Overview Here are the key a...